PNNL | GenomeWeb

PNNL

A new study suggests that EGFR and MAPK protein abundance is the same across cell lines, while the adaptor proteins vary in number.

Researchers also uncovered key pathways and alterations linked to differences in survival.

The organizations will create an integrated omics laboratory to investigate disease biomarkers for new drug therapies.

NEW YORK (GenomeWeb News) – In a paper appearing online today in Science, researchers from the University of California at Berkeley, Lawrence Berkeley National Laboratory, Oak Ridge National Laboratory, and the Pacific Northwest National Laboratory described the slew of microbes that the

By Adam Bonislawski
A team led by researchers at Pacific Northwest National Laboratory has developed a mass spec-based workflow for global analysis of O-linked N-acetylglucosamine, or O-GlcNAc, protein modification.

The new center for Systems and Translational Research on Infectious Disease expects to expand its roster by more than 20 scientists over the next 12 months, according to its research manager.

Movers & Shakers

Premium

Wei-Jun Qian

The approach could be a breakthrough in the identification of new species with applications in both the bioremediation and environmental arenas, as well as in the clinic, said the first author of a study describing the method.

The study is the first to look at a clinical biomarker to assess potential ecological risk assessment. Eventually, they hope to develop an assay that hydropower operators can use to evaluate how their facilities may be affecting the survival of fish populations, especially those that may be endangered.

A Big Team for a Big Lab

Premium

Richard Smith is one PI who asks his postdocs to check their egos at the door for the benefit of the group, but the time they spend in his lab guarantees to benefit them all as individuals.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.